Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00404287
Recruitment Status :
(Funding not enough to complete the study)
Atherosclerosis and aortic stenosis share inflammatory etiopathogenic characteristics in common. We hypothesized that statins therapy would decrease inflammatory markers concentrations in patients with degenerative aortic stenosis and halt the haemodynamic progression of the disease.
Condition or disease
Aortic Valve Stenosis
This study will be a prospective, phase IV-III, randomized, double blinded, active controlled study, to evaluate the efficacy of fluvastatin on inflammatory markers in the haemodynamic progression of degenerative aortic stenosis. We hypothesized that statins therapy would decrease inflammatory markers concentrations in patients with degenerative aortic stenosis and halt the haemodynamic progression of the disease. Eligible patients with degenerative aortic stenosis will be randomized 1:1 to fluvastatin 80 mg once daily or placebo. The treatment should be continued until the study end (12 months). Follow up investigations will be performed after 3 months and at the end of the study (12 months).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age ≥ 18 years
Aortic stenosis defined as aortic valve leaflet thickening with reduced systolic opening (maximum aortic jet velocity >2 m/s)
Written informed consent to participate in the study
Patients capable to follow all conditions along the study.
Symptomatic patients caused by aortic stenosis.
Patients on statins anytime in the year before inclusion.
Patients diagnosed of dyslipidemia requiring statins.
Temperature ³37,8 ºC in the week before inclusion.
Any cardiovascular event succeeding in the three months before inclusion
Renal failure requiring hemodialysis
Any inflammatory noncardiac diseases or other reasons known to influence the study biomarkers concentrations.
Any surgery succeeding in the three months before inclusion.
Patients with any hepatopathy that in the view of the investigator prohibits participation in the study.
Patients with known muscular disease.
Patients with any severe medical condition that in the view of the investigator prohibits participation in the study
Use of corticoids, immunosuppressors or non steroid drugs.
Any known sensitivity to study drug (fluvastatin) or class of study drug.
Patients participating in any study in the last year.
Women of childbearing potential not using the contraception method(s) specified in this study, suspicion of pregnancy, as well as women who are breastfeeding